The Antitrust Prescription
The Antitrust Prescription covers antitrust and other economic issues affecting companies in the pharmaceutical industry. In this blog, Edgeworth’s experts provide legal practitioners and pharmaceutical company leaders with the latest economic insights and information impacting business in this constantly-evolving industry.
- Blog, 07.26.2023
In this new article for The Antitrust Prescription, our pharmaceutical economics team discusses Amgen’s proposed acquisition of Horizon and the FTC’s broader approach to challenging conduct under Section 5 of the FTC Act.
- Blog, 05.30.2023
In this edition of The Antitrust Prescription, our Pharmaceutical Economics team discusses Merck and Glenmark's settlements with direct purchasers, end payors, and retailers worth over a combined $600 million.
- Blog, 03.15.2023
In this article, Dr. George Korenko and Dr. Tram Nguyen discuss a brief history of the numerosity standards and the potential implications of recent decisions in pharmaceutical antitrust matters.